The relevance of synuclein autoantibodies as a biomarker for Parkinson's disease

[1]  Anne K. Braczynski,et al.  Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo , 2022, Biomolecules.

[2]  S. Kügler,et al.  Dementia with Lewy bodies-associated ß-synuclein mutations V70M and P123H cause mutation-specific neuropathological lesions. , 2021, Human molecular genetics.

[3]  Jianhong Wang,et al.  Differential Circulating Levels of Naturally Occurring Antibody to α-Synuclein in Parkinson’s Disease Dementia, Alzheimer’s Disease, and Vascular Dementia , 2020, Frontiers in Aging Neuroscience.

[4]  S. Kügler,et al.  Dopamine promotes the neurodegenerative potential of β‐synuclein , 2020, Journal of neurochemistry.

[5]  B. Pakkenberg,et al.  Distinct Autoimmune Anti-α-Synuclein Antibody Patterns in Multiple System Atrophy and Parkinson’s Disease , 2019, Front. Immunol..

[6]  J. Hoozemans,et al.  Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology , 2019, Acta Neuropathologica.

[7]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[8]  M. Clatworthy,et al.  A Systematic Review and Meta-Analysis of Alpha Synuclein Auto-Antibodies in Parkinson's Disease , 2018, Front. Neurol..

[9]  Suneil K. Kalia,et al.  Emerging disease‐modifying strategies targeting α‐synuclein for the treatment of Parkinson's disease , 2018, British journal of pharmacology.

[10]  J. Trojanowski,et al.  Measurements of auto‐antibodies to α‐synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease , 2018, Journal of neurochemistry.

[11]  R. Dodel,et al.  Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood , 2018, Journal of Neuroimmunology.

[12]  A. Shalash,et al.  Elevated Serum α-Synuclein Autoantibodies in Patients with Parkinson’s Disease Relative to Alzheimer’s Disease and Controls , 2017, Front. Neurol..

[13]  B. Pakkenberg,et al.  Autoimmune antibody decline in Parkinson’s disease and Multiple System Atrophy; a step towards immunotherapeutic strategies , 2017, Molecular Neurodegeneration.

[14]  S. Mallal,et al.  T cells of Parkinson’s disease patients recognize α–synuclein peptides , 2017, Nature.

[15]  I. Horváth,et al.  Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels. , 2017, ACS chemical neuroscience.

[16]  L. Sechi,et al.  Humoral cross reactivity between α-synuclein and herpes simplex-1 epitope in Parkinson's disease, a triggering role in the disease? , 2016, Journal of Neuroimmunology.

[17]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[18]  D. Berg,et al.  Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson’s Disease: Sources of (Error) Variance in Biomarker Assays , 2014, PloS one.

[19]  Jason J. Davis,et al.  An impedimetric assay of α-synuclein autoantibodies in early stage Parkinson's disease , 2014 .

[20]  A. López de Munain,et al.  Epitope Mapping of Antibodies to Alpha-Synuclein in LRRK2 Mutation Carriers, Idiopathic Parkinson Disease Patients, and Healthy Controls , 2014, Front. Aging Neurosci..

[21]  D. Berg,et al.  Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson’s Disease Patients and Controls , 2014, PloS one.

[22]  F. Jessen,et al.  Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease , 2013, Neurology.

[23]  D. Loeffler,et al.  α-Synuclein and Anti-α-Synuclein Antibodies in Parkinson’s Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls , 2012, PloS one.

[24]  L. Dang,et al.  Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity. , 2012, International immunopharmacology.

[25]  Xiliang Luo,et al.  The robust electrochemical detection of a Parkinson's disease marker in whole blood sera , 2012 .

[26]  K. Yanamandra,et al.  Correlation between Protective Immunity to ␣ -synuclein Aggregates, Oxidative Stress and Inflammation Institute of General Pathology and Pathophysiology And , 2022 .

[27]  J. Jankovic.  Current concepts in Parkinson's disease and other movement disorders. , 2012, Current opinion in neurology.

[28]  I. Santana,et al.  Montreal Cognitive Assessment: influence of sociodemographic and health variables. , 2012, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[29]  L. Stefanis.  α-Synuclein in Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[30]  T. Kamitani,et al.  Improved Immunodetection of Endogenous α-Synuclein , 2011, PloS one.

[31]  Rolandas Meskys,et al.  α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients , 2011, PloS one.

[32]  K. Yanamandra,et al.  Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression , 2011, Journal of Neuroimmunology.

[33]  S. Inoue,et al.  A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain , 2010, Nature communications.

[34]  D. Loeffler,et al.  Specific antibodies to soluble alpha‐synuclein conformations in intravenous immunoglobulin preparations , 2010, Clinical and experimental immunology.

[35]  F. Salawu,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management. , 2010, Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria.

[36]  Paolo Casali,et al.  Nature and functions of autoantibodies , 2008, Nature Clinical Practice Rheumatology.

[37]  R. Barbour,et al.  Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood , 2008, Neurodegenerative Diseases.

[38]  John Q. Trojanowski,et al.  -synuclein modulates -synuclein neurotoxicity by reducing -synuclein protein expression , 2006 .

[39]  Sebastian Doniach,et al.  Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.

[40]  J Q Trojanowski,et al.  Synucleinopathies: clinical and pathological implications. , 2001, Archives of neurology.

[41]  P. V. VAN MUNSTER,et al.  A turbidimetric immuno assay (TIA) with automated individual blank compensation. , 1977, Clinica chimica acta; international journal of clinical chemistry.

[42]  Ambra Stefani,et al.  Idiopathic REM sleep behaviour disorder and neurodegeneration — an update , 2018, Nature Reviews Neurology.

[43]  L. Rakić,et al.  α-Synuclein is expressed in different tissues during human fetal development , 2007, Journal of Molecular Neuroscience.